Angioplasty or Surgery for Multivessel Coronary Artery Disease: Comparison of Eligible Registry and Randomized Patients in the EAST Trial and Influence of Treatment Selection on Outcomes

• Published in: The American journal of cardiology 1997-06, Vol.79 (11), p.1453-1459
• Main Authors: King, Spencer B, Barnhart, Huiman X, Kosinski, Andrzej S, Weintraub, William S, Lembo, Nicholas J, Petersen, Jackie Y, Douglas, John S, Jones, Ellis L, Craver, Joseph M, Guyton, Robert A, Morris, Douglas C, Liberman, Henry A
• Format: Article
• Language: English
• Subjects: Angioplasty; Biological and medical sciences; Cardiology. Vascular system; Cardiovascular disease; Comparative studies; Coronary heart disease; Heart; Medical sciences; Surgery
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/S0002-9149(97)00170-7

The Emory Angioplasty versus Surgery Trial (EAST) showed that multivessel patients eligible for both percutaneous transluminal coronary angioplasty (PTCA) and coronary bypass surgery (CABG) had equivalent 3-year outcomes regarding survival, myocardial infarction, and major myocardial ischemia. Patients eligible for the trial who were not randomized because of physician or patient refusal were followed in a registry. This study compares the outcomes of the randomized and registry patients. Of the 842 eligible patients, 450 did not enter the trial. Their baseline features closely resembled those of the randomized patients and follow up was performed using the same methods. In the registry there was a bias toward selecting CABG in patients with 3-vessel disease (84%) and PTCA in patients with 2-vessel disease (54%). Three-year survival for the registry patients was 96.4%, which was better than the randomized patients, 93.4% (p = 0.044). Angina relief in the registry was equal for CABG and PTCA patients and was better for the PTCA registry (12.4%) than PTCA randomized patients (19.6%) (p = 0.079). Thus, the registry confirms that EAST is representative of all eligible patients and does not represent a low-risk subgroup. Since baseline differences were small, improved survival in the registry may be due to treatment selection. Physician judgment, even in patients judged appropriate for clinical trials, remains a potentially important predictor of outcomes. Eligible but nonrandomized patients (the registry) in Emory Angioplasty versus Surgery Trial (EAST) were similar in most respects to those in the randomized trial and the treatment chosen favored surgery for 3-vessel disease. Overall survival of these registry patients was similar for angioplasty and surgery treated patients and was superior to those in the randomized cohort even after adjusting for measured baseline variables.